Neuromyelitis optica in a man without predisposing factors
DOI:
https://doi.org/10.32818/reccmi.a9n3a14Keywords:
devic’s opticomyelitis, aquaporin-4, neuromyelitis opticaAbstract
Neuromyelitis optica, or Devic's disease, is an inflammatory demyelinating disorder of the central nervous system
characterized by longitudinally extensive myelitis and optic neuritis. It is distinguished by the presence of anti-AQP4
antibodies and it can follow a severe clinical course without early treatment. We present the case of a middle-aged
patient who developed ocular pain, followed by trunk hypoesthesia and lower limb weakness, impairing gait. Imaging
revealed longitudinally extensive myelopathy, and anti-AQP4 antibodies confirmed the diagnosis. This case
highlights the importance of early diagnosis to prevent relapses and improve the patient’s prognosis.
Downloads
Metrics
References
Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis
optica. Nature Reviews Disease Primers. 2020; 6(1): 85. doi: https://doi. DOI: https://doi.org/10.1038/s41572-020-0195-8
org/10.1038/s41572-020-0214-9 (último acceso dic. 2024).
Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W. The
immunology of neuromyelitis optica – Current knowledge, clinical implications,
controversies and future perspectives. International Journal of
Molecular Sciences. 2016; 17(3). doi: https://doi.org/10.3390/ijms17030273 DOI: https://doi.org/10.3390/ijms17030273
(último acceso dic. 2024).
Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo
Clinic Proceedings. 2017; 92(4): 663–679. doi: https://doi.org/10.1016/j.mayocp. DOI: https://doi.org/10.1016/j.mayocp.2016.12.014
12.014 (último acceso dic. 2024).
Paul S, Mondal GP, Bhattacharyya R, Ghosh KC, Bhat IA. Neuromyelitis optica
spectrum disorders. Journal of the Neurological Sciences. 2021; 420:
doi: https://doi.org/10.1016/j.jns.2020.117225 (último acceso dic. DOI: https://doi.org/10.1016/j.jns.2020.117225
.
Prüss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;
(12): 798–813. doi: http://doi.org/10.1038/s41577-021-00543-w (último DOI: https://doi.org/10.1038/s41577-021-00543-w
acceso dic. 2024).
Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K,
et al. Update on the diagnosis and treatment of neuromyelits optica spectrum
disorders (NMOSD) – revised recommendations of the Neuromyelitis
Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
J Neurol. 2023; 270(7): 3341–3368. doi: http://doi.org/10.1007/s00415-023-
-0 (último acceso dic. 2024).
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J,
Häußler V, et al. Update on the diagnosis and treatment of neuromyelitis
optica spectrum disorders (NMOSD) – revised recommendations
of the Neuromyelitis Optica Study Group (NEMOS). Part II:
Attack therapy and long-term management. J Neurol. 2023; 271(1):
–76. doi: http://doi.org/10.1007/s00415-023-11910-z (último acceso DOI: https://doi.org/10.1007/s00415-023-11910-z
dic. 2024).
Maciak K, Pietrasik S, Dziedzic A, Redlicka J, Saluk-Bijak J, Bijak M, et al. Th17-
related cytokines as potential discriminatory markers between neuromyelitis
optica (Devic’s disease) and multiple sclerosis-A review. Int J Mol Sci.
; 22(16): 8946. doi: https://doi.org/10.3390/ijms22168946 (último acceso DOI: https://doi.org/10.3390/ijms22168946
dic. 2024).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jorge Hernández-Navas, Luis Dulcey-Sarmiento, Jaime Gómez-Ayala, Juan Therán-Leon, Valentina Ochoa-Castellanos
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
